Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q4 FY2013 Earnings Presentation
18 slides from Torrent Pharmaceuticals's earnings presentation, 2013
Slide 1: Investor Presentation Q4 FY 2012-13
TORRENT PHARMACEUTICALS LTD. Investor Presentation Q4 FY 2012-13
Slide 2: Caveat
Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre
Slide 3: Contents
Contents 1. Performance Highlights 2. Financials 3. Business Segments – India – International 4. Facilities – Expansion Plan
Slide 4: Q4 FY13 Highlights
Q4 FY13 Highlights • Revenues at ` 871 Cr vs. ` 674 Cr, growing at 29% • Domestic revenue growth of 9% • International operations growing at 34% • Europe & US markets key contributors to growth of international operations • PBT at ` 159 Cr vs. ` 1 Cr in Q4 FY12 in lieu of exceptional items; adjusted
Slide 5: Financials
Financials
Slide 6: Revenue Progression
Revenue Progression ` Cr Particulars Q4 Q4 12-13 11-12 12 - 13 11 - 12 India 218 200 1024 909 Gwth % 9% 13% International 526 394 1834 1482 Gwth % 34% 24% Brazil 133 125 502 477 Europe (Incl. Germany) 211 132 650 542 USA 92 64 355 216 ROW (Incl. Russia & CIS) 82 67 297 227 Contract Manufacturing 94
Slide 7: P&L
P&L ` Cr Q4 Q4 P a r t ic u lar s 12-13 11-12 12 - 13 11 - 12 Re v e n u e s 8 71 67 4 3,21 2 2 ,6 9 6 Co gs 2 43 22 2 92 6 863 % R ev e n u e s 2 8% 33 % 29 % 32% S G & A S pe n d 2 67 22 0 96 5 778 % R ev e n u e s 3 1% 33 % 30 % 29% Emp loy e e Co s t 1 64 14 4 62 3 534 % R ev e n u e s 1 9% 21 %
Slide 8: Balance Sheet
Balance Sheet ` Cr Particulars 31-Mar-12 % 31-Mar-13 % ∆ EQUITY AND LIABILITIES Shareholders' Funds 1,194 70% 1,590 71% 396 Minority Interest 4 0% 0 0% (3) Non-current liabilities 500 29% 651 29% 151 TOTAL 1,697 100% 2,242 100% 545 ASSETS Net Fixed Assets 916 54% 1,105 49% 189 Investments 38 2% 0 0%
Slide 9: Business Segments: India
Business Segments India
Slide 10: India: Highlights & Growth Drivers
India Highlights & Growth Drivers ` Cr Q4 Q4 India 12-13 11 - 12 12 - 13 11 - 12 Revenues 218 200 1024 909 % Growth 9% 13% 9% • Q4 FY 13 Highlights • New DPCO 2013 policy notified. Price notification on NLEM drugs expected anytime. • Impact of new policy on not expected to be significant • QTR MAR 1
Slide 11: Business Segments: International Operations
Business Segments International Operations
Slide 12: Brazil: Highlights & Growth Drivers
Brazil Highlights & Growth Drivers ` Cr Q4 Q4 Brazil 12-13 11-12 12 - 13 11 - 12 Revenues 133 125 502 477 % Growth 7% 5% 34% • Q4 FY 13 Highlights • Covered Market growth : 4%, Torrent growth : 6%, Internal growth: 7%, • Reai growth – 11% during the quarter • Overall Market slow down • 2012-13 CM Gw
Slide 13: USA: Highlights & Growth Drivers
USA Highlights & Growth Drivers ` Cr Q4 Q4 USA 12-13 11-12 12 - 13 11 - 12 Revenues 92 64 355 216 % Growth 43% 64% 89% • Q4 FY 13 Highlights • Revenue growth of 33% on constant currency basis • Received 6 ANDA approvals during the year • 43 ANDA approvals (including 7 tentative approvals) and pipeli
Slide 14: Europe inc Heumann: Highlights & Growth Drivers
Europe inc Heumann Highlights & Growth Drivers ` Cr Europe + Q4 Q4 12-13 11-12 Heumann 12 - 13 11 - 12 Revenues 211 132 650 542 % Growth 59% 20% 16% • Q4 FY 13 Highlights • Euro sales growth of 48%. • Europe and Greenfield major contributors to growth. • Growth Drivers • Heumann successful in winnin
Slide 15: ROW inc RCIS: Highlights & Growth Drivers
ROW inc RCIS Highlights & Growth Drivers ` Cr Q4 Q4 ROW+RCIS 12-13 11-12 12 - 13 11 - 12 Revenues 82 67 297 227 % Growth 23% 85% 16% • Q4 FY13 Highlights • Revenue growth of 14% on constant currency basis. • Growth Drivers • Middle East/ Africa Region Delivering the growth being an upcoming market •
Slide 16: Facilities – Expansion Plan
Facilities – Expansion Plan
Slide 17: Facilities – Expansion Plan: Dahej SEZ
Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1100 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 750 crores, First Regulatory Approval: Q1’14-15 • Pha
Slide 18: Thank You
Thank You
Torrent Pharmaceuticals — Q4 FY2013 Earnings Presentation on 6ix